#	Pagina
attuale pagina	/open-h2020/projects/223689/index.html

Opendata, web and dolomites

KINETICfinder SIGNED

KINETICfinder: A disruptive method to determine kinetic profiles in drug discoveries

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

KINETICfinder project word cloud

Explore the words cloud of the KINETICfinder project. It provides you a very rough idea of what is the project "KINETICfinder" about.

utilise clinical kineticfinder drug performed time times pain 50 base reproducible small accurate extremely bringing 40 kinases recognizing final experimental efficacy reduce drugs stages massive capables niche generating toxicity technologies market amount strategy kinetic thousands takes disorders slow gpcrs inflammation cardiovascular companies plan enzymlogic trials neurodegenerative 600 company innovation faster pharmaceutical affordable diabetes 80 nowadays business external otherwise cancer provides processivity methodology lack customers validation commercialization elaboration kinase auxiliar costly created 12 prizes diseases analysed

Project "KINETICfinder" data sheet

The following table provides information about the project.

Coordinator	ENZYMLOGIC SL Organization address address: C/ SANTIAGO GRISOLIA 2 RECINTO PARQUE TECNOLOGIC city: TRES CANTOS MADRID postcode: 28760 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Spain [ES]
Total cost	71˙429 €
EC max contribution	50˙000 € (70%)
Programme	1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
Code Call	H2020-SMEInst-2018-2020-1
Funding Scheme	SME-1
Starting year	2019
Duration (year-month-day)	from 2019-06-01 to 2019-11-30

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	ENZYMLOGIC SL ENZYMLOGIC SL Organization address address: C/ SANTIAGO GRISOLIA 2 RECINTO PARQUE TECNOLOGIC city: TRES CANTOS MADRID postcode: 28760 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ES (TRES CANTOS MADRID)	coordinator	50˙000.00

Map

Project objective

Bringing Bringing a new drug to the market costs 2,600 M€ and it takes 12 years. In addition, around 80% of drugs under research do not reach clinical trials (due to toxicity or lack of efficacy). ENZYMLOGIC was created with the aim of being a company in the niche of kinetic analysis. They have developed KINETICfinder: an experimental, robust, accurate and reproducible methodology that provides drug kinetic analyses in a massive way and at affordable cost, so it is possible to utilise it in early research stages, when thousands of drugs are involved. ENZYMLOGIC has been focused on providing auxiliar external analysis having pharmaceutical companies as customers. Nowadays, there are no comparable technologies capables of generating this amount of information with this level of processivity (number of drugs analysed at the same time). Currently, this analysis is extremely slow and costly, thus it is carried out in the final stages of the research, with just a small number of drugs. Otherwise, the number of different drugs they can analyse is 10 times higher and 10 times faster than other kinetic analysis (processivity). KINETICfinder can reduce the time and cost by 50% from the research phase of a new drug to the market phase. KINETICfinder already makes it possible to analyse 30 kinase targets (involved in cancer), and the next step is to work with GPCRs (neurodegenerative disorders, inflammation, pain, cardiovascular diseases and diabetes). 40% of the existing drugs are aimed at GPCRs. ENZYMLOGIC has obtained several prizes recognizing innovation and potential growth. The objective in phase I will be the validation of the use of KINETICfinder for working with GPCRs having as a base the previous work performed with kinases. To achieve this, the associated tasks shall be: validation of the method working with GPCRs having as a base the previous work performed with kinases, detailed market study & business plan elaboration and validation of commercialization strategy.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "KINETICFINDER" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "KINETICFINDER" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

RDNA (2019)

Empowering New Venture Growth - RDNA

MEDIVAC (2019)

Machine learning software to design personalized neoantigen vaccines tailored to specific vaccine delivery systems

Project Tracworx (2019)

Tracworx is a data analytics tool that allows you to establish bottlenecks in your patient flow, while understanding your efficiencies and ultimately your true capacity.